Shukra Pharmaceuticals Ltd.

As of June 30, 2026, Shukra Pharmaceuticals Ltd. carries a market capitalization of 12.70B, placing it among publicly traded companies globally. Its enterprise value stands at 12.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shukra Pharmaceuticals Ltd. has 439.61M shares outstanding.

As of June 30, 2026, Shukra Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 37.61.

As of June 30, 2026, Shukra Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 27.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 16.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.70B versus a market cap of 12.70B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.59M in revenue per employee across its workforce of 163.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Shukra Pharmaceuticals Ltd. recorded 115.98M in income tax expense. That works out to an effective tax rate of 25.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 455.83M, leaving 339.85M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Shukra Pharmaceuticals Ltd.'s stock has gained approximately 64.35% over the past 52 weeks. The 50-day moving average sits at 55.22, while the 200-day moving average is 40.90.

Over the twelve months ended June 30, 2026, Shukra Pharmaceuticals Ltd. generated 748.59M in revenue and converted that into 339.85M in net income, yielding earnings per share of 0.77. EBITDA reached 465.61M, while operating income came in at 428.23M.

Over the twelve months ended June 30, 2026, Shukra Pharmaceuticals Ltd. posted a gross margin of 81.91, reflecting its pricing power and cost economics. The operating margin of 57.20 and net profit margin of 45.40 provide insight into operational efficiency.

Shukra Pharmaceuticals Ltd.'s most recent stock split took place on March 21, 2025 with a 1:10 split ratio.